





United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/853,188	05/09/2001	Ilham Mohamed Saleh Saeed Abuljadayel	674528-2003.1	6161
759	90 09/04/2002			
Thomas J. Kowalski			EXAMINER	
FROMMER LAWRENCE & HAUG LLP 745 Fifth Avenue			CANELLA, KAREN A	
New York, NY	10151		ART UNIT	PAPER NUMBER
			1642	10
			DATE MAILED: 09/04/2002	\mathcal{U}

Please find below and/or attached an Office communication concerning this application or proceeding.



Application No. 09/853,188

Applicant(s)

Examiner

Karen Canella

Art Unit

1642

Abuljadayel



Office Action Summary

	The MAILING DATE of this communication appear	rs on the cover sheet with the correspondence address		
	for Reply			
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE <u>30 days</u> MONTH(S) FROM		
	ions of time may be available under the provisions of 37 CFR 1.136 (a). In a date of this communication.	no event, however, may a reply be timely filed after SIX (6) MONTHS from the		
If the pIf NO pFailureAny re	period for reply specified above is less than thirty (30) days, a reply within th	nd will expire SIX (6) MONTHS from the mailing date of this communication. e application to become ABANDONED (35 U.S.C. § 133).		
Status	patent term educations. Ged 67 CTT 1.75-467.			
1) 🗆	Responsive to communication(s) filed on			
2a) 🗌	This action is FINAL. 2b) ☑ This act	ion is non-final.		
3) 🗆	Since this application is in condition for allowance e closed in accordance with the practice under <i>Ex pai</i>	except for formal matters, prosecution as to the merits is reference Quayle, 1935 C.D. 11; 453 O.G. 213.		
Disposi	tion of Claims			
4) 💢	Claim(s) <u>1-97</u>	is/are pending in the application.		
4	a) Of the above, claim(s)	is/are withdrawn from consideration.		
5) 🗆	Claim(s)	is/are allowed.		
6) 🗆	Claim(s)	is/are rejected.		
7) 🗆	Claim(s)	is/are objected to.		
8) 💢	Claims <u>1-97</u>	are subject to restriction and/or election requirement.		
Applica	ition Papers			
9) 🗆	The specification is objected to by the Examiner.			
10)□	The drawing(s) filed on is/are	a) accepted or b) bobjected to by the Examiner.		
	Applicant may not request that any objection to the de	rawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11)	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.		
	If approved, corrected drawings are required in reply t	o this Office action.		
12)	The oath or declaration is objected to by the Exami	ner.		
Priority	under 35 U.S.C. §§ 119 and 120			
13)□	Acknowledgement is made of a claim for foreign pr	iority under 35 U.S.C. § 119(a)-(d) or (f).		
a)□] All b)□ Some* c)□ None of:			
	1. \square Certified copies of the priority documents have	e been received.		
	2. \square Certified copies of the priority documents have	e been received in Application No		
	application from the International Burea			
_	ee the attached detailed Office action for a list of the			
	Acknowledgement is made of a claim for domestic			
_	The translation of the foreign language provisiona			
15)∐ ^******	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. 33 120 and/or 121.		
Attachm	lent(s) tice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).		
	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)		
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 6) Other:				
		· · · · · · · · · · · · · · · · · · ·		

Page 2

Application/Control Number: 09/853,188

Art Unit: 1642

DETAILED ACTION

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-43, drawn to a device for increasing the relative number of undifferentiated cells in a cell population classified in class 435, subclass 284.1.
 - II. Claims 44-97, drawn to a method for preparing an undifferentiated cell comprising retro differentiating a more committed cell to a less committed cell, classified in class 435, subclass 377.
- 2. The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as process and apparatus for its practice. The inventions are distinct if it can be shown that either: (1) the process as claimed can be practiced by another materially different apparatus or by hand, or (2) the apparatus as claimed can be used to practice another and materially different process. (MPEP § 806.05(e)). In this case the apparatus of Invention I can be used in a method of preparing a transformed cell line.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter and because the searches required for the groups are not co-extensive, restriction for examination purposes as indicated is proper.

- 3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any

Application/Control Number: 09/853,188

Art Unit: 1642

amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

- 5. Claims 1-97 are generic to a plurality of disclosed patentably distinct species comprising
 - A. (i) Hematopoietic cells,
 - (ii) neuronal cells,
 - (iii) epithelial cells,
 - (iv) mesenchymal cells,
 - (v) endodermal cells,
 - (vi) embryonic cells;
 - B. (i) CD34⁺ cell surface marker,
 - (ii) HLA-DR cell surface marker,
 - (iii) CD38⁻ cell surface marker,
 - (iv) CD117 cell surface marker,
 - (v) AC113 cell surface marker,
 - (vi) CD90 cell surface marker,
 - (vii) CD45low cell surface marker;
 - C. (i) CFC-T cells and T-cells,
 - (ii) CFC-B cells and B-cells,
 - (iii) CFC-Eosin cells,
 - (iv) CFC-Bas cells,
 - (v) CFC-GM cells,
 - (vi) CFC-MEG cells,
 - (vii) CFC-E cells.
- 6. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from Group A, and a single disclosed species from Group B even though this requirement is traversed. In the

Page 4

Application/Control Number: 09/853,188

Art Unit: 1642

event that applicant elects hematopoietic cells from Group A, an additional election from Group C is required.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Canella whose telephone number is (703) 308-8362. The examiner can normally be reached on Monday through Friday from 8:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Karen A. Ganella Karen A. Canella, Ph.D.

Patent Examiner, Group 1642

September 1, 2002